Close menu




Biotech

Photo credits: pixabay.com

Commented by Stefan Feulner on August 21st, 2023 | 07:15 CEST

Meyer Burger, Saturn Oil + Gas, CureVac - Incisive events

  • Mining
  • Oil
  • Biotechnology
  • Technology

The past week in the stock market, due to the earnings season for the year's first half, brought surprises on both sides. Some companies were able to shine despite uncertainties on the economic and geopolitical side and face a golden future due to a significant undervaluation. Speaking of the future: Due to weaker market conditions, one company after another is leaving the old contingent to take advantage of better conditions overseas.

Read

Commented by Armin Schulz on August 16th, 2023 | 05:40 CEST

BioNTech, Defence Therapeutics, Bayer - Who will have trend-setting news first?

  • Biotechnology
  • Pharma

Pharmaceutical and biotech stocks are among the most volatile sectors in the financial markets. Single news stories about new developments or product announcements can not only cause short-term price swings but also have long-term implications, increasing both risk and opportunity for investors. If a breakthrough drug is developed, old preparations can become obsolete - this is good for the innovative company but detrimental to established market participants. As an investor, it is advisable to select specific companies and anticipate directional news through some research.

Read

Commented by Fabian Lorenz on August 9th, 2023 | 07:00 CEST

After BioNTech shock: Evotec, Morphosys and Cardiol Therapeutics emerge as the new biotech favorites

  • Biotechnology

BioNTech startled investors and analysts with its quarterly figures on Monday. Yet the biotech segment has actually developed positively in recent months. Several stocks are currently going full throttle, and S&P's sector index also outperformed the S&P 500 and MSCI World in July. This could finally signal the end of the underperformance of recent years, and biotech stocks could be celebrating a comeback. On the German stock charts, Evotec and Morphosys are among the high flyers. Both shares have performed strongly since April. Cardiol Therapeutics also looks promising from a technical chart perspective, and analysts see a price potential of over 200%. In contrast, there is currently no reason to buy BioNTech. Instead, investors should also bet on strength.

Read

Commented by André Will-Laudien on August 7th, 2023 | 07:55 CEST

Wild times - quarterly figures on the move! Tupperware, Defence Therapeutics, PayPal and Amazon under the magnifying glass!

  • Biotechnology
  • Software
  • Investments

After a pronounced summer rally on the stock markets, there have been individual setbacks in early August. It should come as no surprise that the reaction to quarterly figures can sometimes be more intense. Often, stocks have simply run too far and experienced a healthy consolidation; in the case of Tupperware, the opposite is probably the case. Here, too many speculators have positioned themselves on the short side, and there were hopeful reports. We analyze a few highlights of the last week.

Read

Commented by Stefan Feulner on August 2nd, 2023 | 09:15 CEST

Well positioned for the future - BioNTech, Defence Therapeutics, Sanofi

  • Biotechnology
  • Pharma
  • AI

There is currently a lot of movement in the capital-intensive biotech sector. After second-tier companies, in particular, were hit hard by the effects of tighter monetary policy last year and at times traded below their cash levels, many are now considered hot takeover candidates thanks to their innovative technologies. The well-heeled pharma giants must act to avoid missing out on future blockbusters.

Read

Commented by Stefan Feulner on August 1st, 2023 | 09:00 CEST

Biogen, Cardiol Therapeutics, Evotec - The acquisition wave is rolling

  • Biotechnology
  • Pharma

The biotechnology industry has seen a significant increase in acquisitions and mergers in recent months. Large pharmaceutical companies are looking to expand their portfolios to provide innovative solutions for unmet medical needs. At the same time, despite an increase in value in recent months, acquisition targets are still attractively valued due to the sell-off over the past year.

Read

Commented by Armin Schulz on July 27th, 2023 | 07:15 CEST

BioNTech, Defiance Silver, Vonovia - Waiting for the turnaround

  • Mining
  • Silver
  • Turnaround
  • Biotechnology
  • RealEstate

The stock market is not a one-way street, so it happens time and again that companies that initially performed well run into problems, leading to falling prices. After an extended period of underperformance, bargain hunters often step in, seeking the right entry point to profit from a potential turnaround. One announcement can turn the tide and influence the price of a stock. We have selected three candidates where a turnaround could be imminent, provided an appropriate news catalyst exists.

Read

Commented by Stefan Feulner on July 25th, 2023 | 09:45 CEST

Sartorius, BioNxt Solutions, CENIT AG - Attack from the Second Row

  • Biotechnology
  • Pharma
  • Software
  • Technology

While some of the big caps have already reached new highs in the current stock market year 2023, many undiscovered second-tier stocks are still a long way off. At the same time, companies, most of which rely on disruptive technologies, possess powerful potential. If the ambitious goals are achieved, investors can expect above-average returns.

Read

Commented by Juliane Zielonka on July 21st, 2023 | 07:20 CEST

BioNxt Solutions, Morphosys, Palantir - Innovative therapies for Parkinson's, cancer and soaring with AI

  • Biotechnology
  • Pharma
  • Cancer
  • AI
  • Technology

There are exciting developments in the biotech industry. Thanks to innovative AI technologies, companies like BioNxt Solutions bionxt.com/investors can analyze medical data faster and develop an innovative medical patch that provides Parkinson's patients with faster symptom relief. This patch carries the active ingredient rotigotine and has enormous market opportunities worldwide. Blockbuster-level market opportunities are emerging at Morphosys with regard to its compound pelabresib for the treatment of a rare form of blood cancer. The Phase III trial is expected to deliver results earlier than expected, and analysts see promising opportunities for the drug. According to a study by Bristol Myers Squibb, about 1.85 million new cases of blood cancer are expected worldwide in 2040. Deutsche Bank rated the stock "hold," driving the price up 4.9% this week. Also pushing upward is Palantir. The US company is getting into the drone business thanks to a partnership with Canada's Airmatrix.

Read

Commented by Armin Schulz on July 19th, 2023 | 07:45 CEST

Pfizer, Cardiol Therapeutics, Bayer - Pharma facing turnaround despite drug shortages?

  • Pharma
  • Biotechnology

In mid-June, there was a shortage of 470 prescription drugs in Germany, according to the Federal Institute for Drugs and Medical Devices. However, not only Germany is suffering from a shortage, but all of Europe. Once again, the dependence on China is the underlying cause. The EU is seeking countermeasures, but this will be challenging because capped prices, bureaucracy and rising energy costs make a location like Germany seem less attractive. At the same time, demographic change means that society needs the pharmaceutical industry more and more urgently. Therefore, we look at three companies that aim to heal sick people.

Read